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Abstract
Background: Rift Valley fever virus (RVFV) causes outbreaks of severe disease in livestock and humans throughout Africa
and the Arabian Peninsula. In people, RVFV generally causes a self-limiting febrile illness but in a subset of individuals, it
progresses to more serious disease. One manifestation is a delayed-onset encephalitis that can be fatal or leave the afflicted
with long-term neurologic sequelae. In order to design targeted interventions, the basic pathogenesis of RVFV encephalitis
must be better understood.
Methodology/Principal Findings: To characterize the host immune responses and viral kinetics associated with fatal and
nonfatal infections, mice were infected with an attenuated RVFV lacking NSs (DNSs) that causes lethal disease only when
administered intranasally (IN). Following IN infection, C57BL/6 mice developed severe neurologic disease and succumbed 7–
9 days post-infection. In contrast, inoculation of DNSs virus subcutaneously in the footpad (FP) resulted in a subclinical
infection characterized by a robust immune response with rapid antibody production and strong T cell responses. IN-
inoculated mice had delayed antibody responses and failed to clear virus from the periphery. Severe neurological signs and
obtundation characterized end stage-disease in IN-inoculated mice, and within the CNS, the development of peak virus RNA
loads coincided with strong proinflammatory responses and infiltration of activated T cells. Interestingly, depletion of T cells
did not significantly alter survival, suggesting that neurologic disease is not a by-product of an aberrant immune response.
Conclusions/Significance: Comparison of fatal (IN-inoculated) and nonfatal (FP-inoculated) DNSs RVFV infections in the
mouse model highlighted the role of the host immune response in controlling viral replication and therefore determining
clinical outcome. There was no evidence to suggest that neurologic disease is immune-mediated in RVFV infection. These
results provide important insights for the future design of vaccines and therapeutic options.
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Introduction
Rift Valley fever virus (RVFV) is a zoonotic arbovirus that has
serious public health, veterinary and economic impacts through-
out Africa and the Arabian Peninsula. RVFV outbreaks are often
triggered by periods of heavy rain and the subsequent emergence
of RVFV-infected mosquitoes, and are characterized by the
subsequent widespread abortion storms in livestock. People may
become infected directly by the bite of infected mosquitoes, or by
exposure to infected animal tissues. In humans, RVFV infection is
generally described as a self-limiting febrile illness marked by
severe arthralgia, myalgia, photophobia and headache. Although
most individuals recover without long-term sequelae, some human
infections progress to a serious hepatitis, hemorrhagic syndrome or
delayed onset encephalitis. In these most severely afflicted patients,
case fatality can be greater than 20% [1,2], and survivors of the
encephalitic syndrome frequently suffer from long-term neurolog-
ical complications. Fatal RVFV encephalitic disease was first
documented in the 1974–76 South African outbreak, and has since
been a consistent finding in subsequent epidemics [1,3,4].
RVFV is a member of the family Bunyaviridae, genus Phlebovirus,
and has a tripartite negative-sense RNA genome composed of a
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large (L), a medium (M) and a small (S) segment. The L segment
encodes the RNA-dependent RNA polymerase. The structural
glycoproteins Gn and Gc, as well as a nonstructural protein NSm,
are encoded on the M segment. NSm is thought to function by
inhibiting virus-induced apoptosis [5,6] as well as by mediating
replication in the mosquito vector [7]. The ambisense S segment
encodes the nucleoprotein (N) that is required for RNA synthesis,
and the nonstructural NSs protein. NSs is the major virulence
factor and functions broadly by inhibiting the host immune
response [8] via generalized downregulation of host transcription
[9], post-transcriptional degradation of protein kinase R (PKR)
[10,11] and TFIIH p62 [12], and repression of the interferon-b
(IFNb) promoter [13].
The critical role of NSs in RVFV pathogenesis has been clearly
illustrated in a number of studies, including the RVFV mouse
model. Following infection with wild-type RVFV, C57BL/6J mice
succumb to a fatal hepatitis within 2–3 days of infection, regardless
of the dose or route of administration. In contrast, subcutaneous
inoculation of a highly attenuated virus lacking NSs (DNSs) results in
a widely disseminated infection that is cleared with no indication of
clinical disease. We recently demonstrated that viral clearance and
protection from clinical disease is dependent on a functional CD4+
T cell response. In that study, 30% of mice depleted of CD4+ T cells
succumbed to neurologic disease following DNSs infection, in
association with reduced antibody titers and evidence of altered
CD4+ T cell regulatory function [14]. The results indicated that
severe neurologic disease developed following a reduced systemic
immune response, but also raised the question of whether
neurologic disease resulted from direct viral damage to the CNS
or to pathology resulting from disruption of the blood brain barrier
and an unregulated immune response. To address this question, a
mouse model of RVFV infection with route-dependent disease was
utilized as a platform to explore the differences in the host immune
response between animals that developed fatal RVFV encephalitis
and those that had subclinical infections.
Here we report that intranasal (IN) infection of the highly
attenuated DNSs virus resulted in consistently fatal neurologic
disease 7–9 days after infection, in contrast to the uniformly
subclinical infection that follows subcutaneous DNSs infection.
Intranasal virus inoculation has been commonly utilized in mouse
models of human viral encephalitic diseases, including Herpes
simplex virus [15], influenza A virus [16], Sindbis virus [17],
Venezuelan equine encephalitis virus [18–20], western equine
encephalitis virus [21] and Hendra virus [22]. This method of
inoculation can be a proxy for aerosol exposure, which has been
shown to be an important route of RVFV exposure in laboratory
settings [23], and is thought to play a role in the infection of
individuals handling infected animal tissues. Aerosol exposure of
wild-type RVFV has been shown to cause uniformly fatal disease
in mice [24,25], similar to subcutaneous infection with the same
virus. Use of the DNSs virus model in this study permitted
characterization and direct comparison of the host immune
responses and viral kinetics in mice that developed fatal
encephalitis (IN-inoculation) with those that had a subclinical
infection (FP-inoculation). Fatal infections were associated with
weak systemic immune responses and a subsequent failure to clear
virus from the periphery, and onset of clinical disease correlated
with high viral RNA loads and infiltration of activated T cells in
the CNS. Interestingly, depletion of T cells did not improve
survival, suggesting that in contrast to other encephalitic viruses
[26,27], that RVFV neurologic disease is not immune-mediated.
These results provide important insights into the pathogenesis of
severe RVFV infection that could inform the development of




Animal procedures in this study complied with institutional
guidelines, the US Department of Agriculture Animal Welfare
Act, and the National Institutes of Health Guidelines for the
humane use of laboratory animals. All procedures were approved
by the Centers for Disease Control and Prevention (CDC)
Institutional Animal Care and Use Committee (IACUC) (Proto-
cols 2023 and 2409).
Mice, viruses, and biosafety
All work with infectious RVFV was completed in a biosafety
level (BSL)-3E laboratory. Female 8–10-week-old C57BL/6J mice
were obtained from Jackson Laboratories and were housed within
BSL-3E laboratories in microisolator pans in HEPA filtration
racks, following standard barrier techniques. In all animal
experiments, mice were evaluated for clinical signs of disease at
least once daily, and were euthanized according to a pre-
determined clinical illness scoring algorithm or if found moribund.
Stocks of recombinant RVFV (strain ZH501) lacking NSs (DNSs)
and a GFP-expressing RVFV lacking both NSs and NSm (DNSm/
DNSs:GFP) were produced using reverse genetics and propagated as
previously described [28,29]. Titers of all viral stocks were
determined as tissue culture infective dose 50 (TCID50) on VeroE6
cells and visualized by indirect fluorescent-antibody assay (IFA) using
anti-RVFV hyperimmune mouse ascitic fluid (HMAF) primary
antibody. Virus sequence identity was verified by full-length genome
sequencing with 6-fold redundancy prior to virus use.
Virus inoculations
For virus inoculated intranasally (IN) or subcutaneously in the
left rear footpad (FP), mice were briefly anesthetized with
isofluorane. For the initial LD50 study, mice were inoculated with
10-fold dilutions of virus, ranging from 16105 TCID50 to 10
TCID50 per nare.
Author Summary
Rift Valley fever virus (RVFV) is a mosquito-borne virus that
causes severe disease in people and livestock throughout
Africa and the Arabian Peninsula. Human disease is usually
self-limiting, but a small proportion of individuals develop
fatal encephalitis. The role of the host immune response in
determining disease outcome is largely unknown. In order
to compare the quality and character of immune respons-
es in nonfatal and fatal cases, we used an attenuated RVFV
to inoculate mice by two routes. Subcutaneous inoculation
resulted in a subclinical systemic infection that was rapidly
cleared due to a robust adaptive response. In contrast,
intranasal inoculation stimulated weaker immune respons-
es that failed to control virus replication and culminated in
uniformly fatal encephalitis. With many encephalitic
viruses, the onset of disease is mediated by changes in
blood brain barrier permeability and often, subsequent
injury to the CNS by an uncontrolled immune response.
However, our results suggest that development of RVFV
disease does not depend on either mechanism, but rather
results from direct virus-mediated damage in the CNS.
Future therapeutic drug design should take into account
all possible routes of virus exposure as well as the role of
therapies that boost the adaptive response to better
combat disease.
Aberrant Immune Response Precedes RVFV Disease
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In subsequent experiments, mice infected with DNSs IN
received 16104 or 16105 TCID50 in 10 mL sterile Dulbecco’s
modified Eagle’s medium (DMEM) per nare. Mice infected in the
left rear FP received 2 6 105 TCID50 in 20 mL of sterile DMEM
subcutaneously. Sham-inoculated mice were given sterile DMEM.
Significant differences between survival curves were analyzed
using a log-rank (Mantel-Cox) test (GraphPad Prism; GraphPad
Software, Inc.).
T cell depletions
C57BL/6J mice were depleted of CD4+ and CD8+ T cells using
monoclonal anti-CD4 (GK1.5) and anti-CD8 (YTS169) antibod-
ies, or mock-depleted using an isotype control antibody (LTF2) (all
obtained from Bio X Cell). Antibodies were diluted in sterile
phosphate buffered saline (PBS); 300 mg of GK1.5 and 300 mg of
YTS169 were administered to each mouse intraperitoneally on
days -3 and -1 prior to virus infection. Depletion efficiency was
determined by flow cytometry to be greater than 99%.
Evans blue dye blood-brain barrier (BBB) permeability
assay
One hour prior to euthanasia, mice were injected intraperito-
neally (IP) with 800 mL of 1% Evan’s blue dye. Mice were deeply
anesthetized with isofluorane and perfused with 10 mL of PBS.
Brains were removed and examined for evidence of dye uptake.
Blue coloration of spleens, livers and kidneys were controls for
effective distribution of dye.
Serology
Serum was collected and used for RVFV anti-N IgG ELISA as
described previously [30,31]. Briefly, purified RVFV N protein or
negative control LASV G1 protein was used at a concentration of
200 ng/well. Plates were blocked in blocking buffer (5% skim
milk, 5% fetal bovine serum (FBS) and 0.1% Tween-20 in 1 6
PBS) at 37uC for 1 h. Plates were incubated with serially diluted
sera in blocking buffer for 1 h at 37uC. Plates were washed 3 times
in 1 6PBS with 0.1% Tween-20 (PBST) and incubated with goat
anti-mouse horseradish peroxidase (HRP 1:10,000) (Jackson
ImmunoResearch) in blocking buffer for 1 h. Plates were washed
3 times in PBST and ABTS substrate was added according to
manufacturer’s instructions (KPL Inc.). Reactions were stopped
with the addition of 1% SDS and read at 405 nM. Absolute values
obtained from negative controls were subtracted prior to analysis.
Data were analyzed using 2-way ANOVA with Bonferroni post-
tests (n = 3/group/time point; *p,0.05; **p,0.01; ***p,0.001)
(GraphPad Prism; GraphPad Software, Inc.).
Virus neutralization titers (VNT100)
Stock DNSm/DNSs:GFP virus was diluted to 100 TCID50 in
50 mL DMEM without FBS. Sera were heat-inactivated at 56uC
for 30 min. In a 96-well plate, 1:5, 1:10, 1:20, 1:40, 1:80, 1:160,
and 1:320 serum dilutions were made in 50 mL DMEM. An equal
volume of diluted RVFV was added to diluted sera and samples
were incubated for 1 h at 37uC. A suspension of approximately
36104 VeroE6 cells was added to each well, and the plates were
incubated for 72 h before visualization of GFP positive cells.
VNT100 was defined as the highest dilution that permitted 100%
neutralization of virus input. Data were analyzed using 2-way
ANOVA with Bonferroni post-tests (n = 3/group/time point; *p,
0.05; **p,0.01; ***p,0.001) (GraphPad Prism; GraphPad
Software, Inc.).
Preparation of splenocytes from mouse spleen
At time of euthanasia, spleens were harvested and immedi-
ately placed in sterile Roswell Park Memorial Institute (RPMI)
media. Single cell suspensions were generated by passing
spleens through a 70 mM mesh filter using the blunt end of a
5 cc syringe plunger. Cell suspensions were washed in RPMI
and red blood cells (RBCs) were lysed using RBC Lysis
Buffer according to manufacturer’s instructions (Sigma-Al-
drich). Cells were washed two additional times in PBS and
suspended in RPMI for quantitation of total cells using a
hemocytometer.
Isolation of leukocytes from mouse brain
Whole brains were removed and immediately placed in
sterile RPMI. Brains were macerated with a #10 blade and
single cell suspensions were produced by passing tissue through
a 70 mM filter using the blunt end of a 5 cc syringe. Cells were
suspended in RPMI and layered on a 70/30 Percoll gradient in
a 15 mL conical tube. Gradients were centrifuged at 800 6 g
for 20 minutes. The interface was taken and washed in 1x
Hank’s balanced salt solution (HBSS). RBCs were lysed
according to manufacturer’s instructions (Sigma-Aldrich).
Cells were suspended in either flow buffer or RPMI for
subsequent assays.
Figure 1. Intranasal inoculation results in fatal encephalitic
disease. C57BL/6 mice were inoculated with various doses of Rift
Valley fever virus (RVFV) lacking the NSs gene (DNSs) intranasally (IN) or
subcutaneously in the footpad (FP). (A) FP-inoculated mice survived
with no indication of clinical signs. IN-inoculated mice developed dose-
dependent disease. Survival curves were significantly different (p,
0.0001). (B) All mice that succumbed to DNSs virus IN infection at high
doses (16104 or 16105 TCID50/per nare) had significantly higher viral
RNA loads in the brain than in the liver, as measured by RVFV-specific
qRT-PCR (p,0.0001).
doi:10.1371/journal.pntd.0002874.g001
Aberrant Immune Response Precedes RVFV Disease
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Flow cytometry
Approximately 16105 splenocytes or brain PBMC were stained
in flow buffer (PBS with 3% FBS) using 1:200 dilutions of the
following antibodies: fluorescein isothiocyanate (FITC) anti-CD4
(553651), FITC anti-CD8 (553031), phycoerythrin (PE) anti-CD3
(555275), PE anti-CD45 (553081), PE anti-CD11b (561689),
allophycocyanin (APC) anti-CD69 (560689), or FITC anti-CD19
(561740), all from BD Biosciences. Staining was performed at 4uC
for 20 min and then cells were washed twice in PBS before being
counted. From each well, 50,000 events were collected on an
Accuri Flow Cytometer (BD Biosciences). CFlow Sampler software
(Accuri) was used to gate on the lymphocyte population. CD3 by
CD4 or CD8 plots were then generated, a second gate was placed
to delineate the CD3/4 or CD3/8 T cells, and the expression of
CD69 on these cells was determined. Plot quadrants were set
based upon the patterns observed in unstained cells. Specificity of
staining was confirmed by the concomitant use of appropriate
isotype control antibodies and fluorescence minus-one controls (all
from BD Biosciences). Compensation was performed using single
antibody stains. Three to five animals from each group of mice
were tested independently on each day. Data were analyzed using
2-way ANOVA with Bonferroni post-tests (*p,0.05; **p,0.01;
***p,0.001) (GraphPad Prism; GraphPad Software, Inc.).
B cell ELISPOTS
MultiscreenHTS filter plates (EMD Millipore) were activated
with 35% ethanol, and then washed in sterile PBS. Activated
plates were coated with 1 mg/well of anti-mouse IgG or with
100 mL of inactivated RVFV virus (107 TCID50/mL), and with
200 ng/well of affinity purified glutatione S-transferase (GST)-
tagged RVFV N protein and allowed to bind overnight at 4uC.
Plates were then washed in sterile PBS and 16105 splenocytes
were placed per well with 3 fold dilutions. Cells were incubated for
24 hours at 37uC. Plates were washed with PBS and incubated
with anti-mouse IgG HRP (1:5000 in PBS) for 1 hour at room
temperature and washed 5 times with PBS. Spots were developed
using DAB substrate (Sigma-Aldrich) and plates were read on an
ELISPOT reader using KS ELISPOT software (Zeiss). RVFV-
specific antibody production is presented as relative to total
antibody production. Data were analyzed using 2-way ANOVA
with Bonferroni post-tests (n = 5/group/time point; *p,0.05;
**p,0.01; ***p,0.001) (GraphPad Prism; GraphPad Software,
Inc.).
T cell ELISPOTS
MultiscreenHTS filter plates (EMD Millipore) were activated
with 35% ethanol, and then washed in sterile PBS. Activated
plates were coated with anti-TNFa (BD Biosciences), anti-IL-4,
anti-IL-2, or anti-IFNc (Mabtech Inc.) capture antibodies and
incubated overnight at 4uC. Plates were washed and 16105
splenocytes/well were plated in 2-fold dilutions and incubated for
24 h at 37uC. Plates were washed with PBS and incubated with
biotinylated detection antibodies for 2 h at room temperature.
Plates were washed and incubated with streptavidin HRP for 1 h
at room temperature. After a final series of washes, spots were
detected using DAB substrate (Sigma) and read on an ELISPOT
reader using KS ELISPOT software (Ziess). Data were analyzed
using 2-way ANOVA with Bonferroni post-tests (n = 3/group/
Figure 2. In IN-inoculated mice, virus replication was first apparent in the olfactory bulb 2 dpi and spread caudally, whereas FP-
inoculated mice had low levels of virus RNA present in the brainstem at late time points. Viral RNA loads from 100 mg of (A) olfactory
bulb, (B) cerebrum, (C) cerebellum, and (D) brainstem were quantified by RVFV qRT-PCR and the CT was displayed on an inverted scale. CT cut-off of
40 noted by gray dashed line. (E) The temporal pattern of virus spread in the CNS of IN-inoculated mice. (F) Viral RNA loads from sciatic nerve. Data
represents vRNA loads of 5 mice per group each day.
doi:10.1371/journal.pntd.0002874.g002
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time point; *p,0.05; **p,0.01; ***p,0.001) (GraphPad Prism;
GraphPad Software, Inc.).
Total RNA extraction
Mice were deeply anesthetized with isofluorane, terminally bled
and perfused with 10 mL PBS. Specimens of olfactory bulb,
cerebral cortex, cerebellum, brainstem, liver, spleen, popliteal
lymph node, sciatic nerve and whole blood were collected. RNA
was extracted using MagMax Total RNA Isolation kit (Ambion).
With the exceptions of the sciatic nerve and popliteal lymph node,
in which cases the entire structures were used, approximately
100 mg of tissue were placed directly in lysis buffer and
homogenized using a high-throughput tissue grinder (GenoGrin-
der2000). Approximately 50 mL of whole blood was added directly
to lysis buffer with isopropanol. Homogenates were extracted
using the MagMax Express-96 Magnetic Particle Processor
(Ambion) according to manufacturer’s directions including a
DNase treatment step.
RVFV qRT-PCR
Liver, spleen, sciatic nerve, popliteal lymph node, olfactory bulb,
cerebrum, cerebellum, brainstem and whole blood RNA were tested
by RVFV qRT-PCR as described previously, using 1 mL of total RNA
[29,32,33]. To normalize between samples, 1 mL of total RNA was
used for a ribosomal RNA qRT-PCR assay (ABI Biosciences).
Reactions were run on an ABI 7500 quantitative PCR machine
(ABI Biosciences). Data were analyzed using 2-way ANOVA with
Bonferroni post-tests (n = 5/group/time point; *p,0.05; **p,0.01;
***p,0.001) (GraphPad Prism; GraphPad Software, Inc.).
Inflammatory cytokine gene expression qRT-PCR
RNA extracted from the cerebrum of IN or FP-inoculated mice
was used to determine inflammatory gene expression. Primer
probe sets for IL-6, TNFa, CCL2 and CCL5 (Applied Biosciences)
were used with Superscript III Platinum qRT-PCR reagents
(Invitrogen). Samples were run in 50 mL reactions: 1.5 mL of
primer probe mix was combined with 25 mL Master Mix, 1 mL
Taq enzyme mix, 21.5 mL sterile water and 1 ml of total RNA. To
normalize between samples, 1 mL of total RNA was used for a
GAPDH qRT-PCR assay (ABI Biosciences). Reactions were run
on an ABI 7500 quantitative PCR machine (ABI Biosciences).
Relative fold changes between mock-infected and IN- or FP-
infected animals were determined using the comparative CT
method as described by Schmittgen and Livak [34]. Data were
analyzed using 2-way ANOVA with Bonferroni post-tests (n = 5/
group/time point; *p,0.05; **p,0.01; ***p,0.001) (GraphPad
Prism; GraphPad Software, Inc.).
Histopathology and immunohistochemistry
Whole brains from mice inoculated IN with DNSs virus were
euthanized after development of severe neurologic signs 7 and
8 dpi. Brains were fixed by immersion in 10% neutral buffered
formalin for 7 days. Tissues were processed, paraffin-embedded,
and sectioned following routine methods, and stained with
hematoxylin and eosin (H&E) for histological examination.
Immunohistochemistry (IHC) assays were performed using a
polymer-based indirect immunoalkaline phosphatase detection
system with colorimetric detection of antibody/polymer complex
with Fast Red Chromogen (Thermo Fisher Scientific) as previously
Figure 3. FP-inoculated mice successfully cleared DNSs virus despite high virus RNA levels at early timepoints. Viral RNA loads in (A)
blood, (B) liver, (C) spleen and (D) draining popliteal lymph node. Averages based on 5 mice per group per time point.
doi:10.1371/journal.pntd.0002874.g003
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described [35]. Pre-treatment of tissue sections was applied as
needed using Proteinase K (PK) (Roche, Mannheim, Germany) or
Antigen Retrieval (AR) (Biocare Medical) prior to IHC staining.
Tissues were evaluated using a polyclonal (PK, 1:1000) and a
monoclonal (PK, 1:500) Rift Valley Fever virus antibody provided
by the CDC (SPB). In addition, tissues were evaluated using CD68
(PK, 1:100, DAKO Cytomation), CD3 (AR, 1:100, Dako
Cytomation), CD8 (AR, Ready-to-Use, Leica Microsystems,
UK) and CD20 (PK, 1:200, Dako Cytomation) cellular markers.
Appropriate positive and negative control serum and tissues were
tested in parallel for each assay.
Results
Intranasal inoculation with DNSs virus resulted in
neurologic disease and mortality 7–9 dpi
As described previously [14], subcutaneous FP inoculation of
2.06105 TCID50 DNSs virus resulted in uniform survival with no
indication of clinical signs, whereas mice inoculated with DNSs
virus IN developed dose-dependent clinical disease (p,0.0001;
Figure 1A). Mice infected with the highest virus doses, 2.06105
and 2.06104 TCID50, displayed signs of severe neurologic disease
and consistently succumbed to infection 7–9 dpi (Figure 1A). At
the time of death, IN-inoculated mice had significantly higher
virus RNA loads in the brain relative to the liver (p,0.0001;
Figure 1B). Of the mice given 2.06103 TCID50, 80% succumbed
to infection with a prolonged time to death. Lower doses did not
result in clinical disease. The striking differences between
intranasal and subcutaneous inoculation provided a unique
platform to characterize and compare the immune responses
elicited during fatal and nonfatal infections, respectively.
IN-infected mice rapidly developed high viral RNA loads
in the brain
To determine the kinetics of virus spread within the nervous
system, 5 FP- and 5 IN-inoculated mice were euthanized, perfused
with PBS and samples of olfactory bulb, cortex, cerebellum,
brainstem and sciatic nerves were taken for RVFV-specific qRT-
PCR on 1, 2, 3, 4, 5, 6, 7 and 8 dpi. The olfactory bulbs of all IN-
inoculated mice tested positive for virus RNA 2 dpi and viral RNA
loads steadily increased over time (Figure 2A). Subsequently, virus
RNA was found in the cerebrum (Figure 2B), cerebellum
(Figure 2C) and brainstem (Figure 2D). In contrast, small numbers
of FP-inoculated mice had low levels of virus RNA present
throughout the brain at late points in infection but these virus
RNA loads were significantly lower than IN-inoculated mice. To
better illustrate the temporal pattern of virus spread in the CNS of
IN-inoculated mice, the virus RNA data from the olfactory bulb,
cerebrum and cerebellum are presented together (Figure 2E).
All FP-inoculated mice had significant virus RNA levels present
in the sciatic nerve 2 dpi, whereas all IN-inoculated mice had
RVFV-positive sciatic nerves 5 dpi (Figure 2F). These data are
consistent with both the route of infection (FP-inoculated mice)
and with the dissemination of virus throughout the nervous system
(IN-inoculated mice).
RVF virus RNA loads were significantly higher in
peripheral tissues of FP-versus IN-inoculated mice early in
infection, but levels were indistinguishable after 3 dpi
In order to determine the effect of the route of infection on
peripheral virus kinetics in vivo, we measured viral RNA loads by
qRT-PCR in the blood, liver, spleen and popliteal lymph nodes.
Viral RNA levels were significantly higher in the blood, liver
and spleen of FP- versus IN-inoculated mice 1 dpi (Figures 3A,
3B and 3C, respectively). However, by 3 dpi, blood, liver and
spleen viral RNA loads were indistinguishable between the FP-
and IN-groups. FP-inoculated mice cleared virus from the liver
by 7 dpi but IN-inoculated mice were unable to control virus
replication in the liver. FP-inoculated mice had significantly
Figure 4. FP-inoculated mice had a significantly stronger
humoral response following DNSs virus infection than IN-
inoculated mice. Serum samples were assayed for (A) RVFV anti-N IgG
antibody titers and (B) RVFV neutralizing antibody titers (averages
based on 3 mice per group). Splenocytes were analyzed for (C) RVFV-
specific B cells as determined by ELISPOT (averages based on 5 mice per
group).
doi:10.1371/journal.pntd.0002874.g004
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higher virus RNA loads in the (draining) popliteal lymph node
than IN-inoculated mice 1–3 dpi (Figure 3D), consistent with
the route of infection.
IN-inoculated mice produced lower levels of anti-N IgG
and neutralizing antibodies than FP-inoculated mice
To explore differences in humoral immunity following IN or FP
inoculation, we compared RVFV anti-N IgG and neutralizing
antibody levels and the number of RVFV-specific B cells between
groups on 2, 4, 6 and 8 dpi. Production of IgG and neutralizing
antibodies were delayed by 48 hours in the IN-inoculated mice
relative to the FP-inoculated mice. FP-inoculated mice had
significantly higher IgG titers 8 dpi, the time at which antibody
was first apparent in the IN group (Figure 4A). Only FP-inoculated
mice had a detectable neutralizing antibody response 6 dpi, and
higher levels 8 dpi than IN-inoculated mice (Figure 4B). FP-
inoculated mice also had significantly higher numbers of RVFV-
specific IgG-secreting B cells than IN-inoculated mice 4 and 8 dpi
(Figure 4C).
IN-inoculated mice had significantly more activated CD4+
and CD8+ T cells in the spleen than FP-inoculated mice
As a broad measure of T cell activation, we next evaluated the
relative proportion of CD69+ T cells in the spleen following IN or
FP inoculation. The spleens of FP-inoculated mice had a
significantly higher percentage of CD3+/CD4+ T cells 8 dpi than
IN-inoculated mice (Figure 5A). The percentage of CD3+/CD8+
T cells was also significantly higher in FP-inoculated mice 4 and
8 dpi (Figure 5B). However, CD4+ T cell activation, as measured
by expression of CD69, was higher in IN-inoculated mice than FP-
inoculated mice throughout the course of infection and signifi-
cantly greater 8 dpi (Figure 5C). A similar trend was apparent in
CD69-positive CD8+ T cells; a higher percentage of CD8+ T cells
of IN-inoculated mice expressed CD69 on all 3 days examined
(Figure 5D).
Splenocytes of FP-inoculated mice produced significantly
higher levels of inflammatory cytokines
To evaluate the quality of the cellular immune response, we
measured IFNc, TNFa and IL-2 expression in splenocytes using
ELISPOT assays. Significantly more T cells from FP-inoculated
mice expressed IFNc and TNFa 6 and 8 dpi (Figures 6A and 6B,
respectively). FP-inoculated mice also had more T cells producing
IL-2 6 and 8 dpi, but IN-inoculated mice had higher numbers of
IL-2 expressing T cells 2 dpi (Figure 6C).
IN-inoculated mice have significantly more leukocytes,
and specifically activated T cells, infiltrating the CNS
following DNSs virus infection
Leukocyte migration into the CNS was compared between
groups using flow cytometry. In an initial experiment, IN-
inoculated mice had a significantly higher proportion of CD45+
cells than FP-inoculated mice 7 and 8 dpi (Figure 7A), and the
majority of these appeared to be T cells given positive staining for
CD3 (Figure 7B). In a subsequent experiment, leukocytes were
harvested from brains of IN- and FP-inoculated mice late in
infection, 6 and 8 dpi. In IN-inoculated mice, there were
significantly more CD4+ (Figure 7C) and CD8+ (Figure 7D) T
cells, than in FP-inoculated mice. In brains from the IN group, a
significantly higher percentage of CD4+ T cells were expressing
Figure 5. IN-inoculated mice have a significantly higher percentage of activated T cells in the spleen than FP-inoculated mice. Flow
cytometry was used to determine the proportion of (A) CD3+/CD4+ and (B) CD3+/CD8+ T cells in the spleens of IN- and FP-inoculated mice. The
proportion of T cells that stained positive for activation marker CD69 are shown in (C) CD3+/CD4+/CD69+ and (D) CD3+/CD8+/CD69+.Averages based
on groups of 3 mice per time point.
doi:10.1371/journal.pntd.0002874.g005
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CD69 (Figure 7E). Similarly, on 6 and 8 dpi, a striking number of
CD8+ T cells were also CD69+ in the brains of IN-inoculated mice
(Figure 7F).
RVFV infection did not alter BBB permeability
Given the early neuroinvasion and increased numbers of
leukocytes seen in the brains of IN-inoculated mice, we sought
to determine if RVFV infection resulted in an increase in BBB
permeability. 5 FP- and 5 IN-inoculated mice were injected with
Evans blue dye one hour prior to euthanasia on 1, 2, 3, 4, 5, 6, 7
and 8 dpi. Mice were then anesthetized and completely perfused
with PBS, and whole brains were removed. No blue dye coloration
was seen in the brains from FP- or IN-inoculated mice at any time
point (data not shown) indicating that there was no breakdown of
the blood brain barrier during infection. Blue coloration of liver,
spleen and kidneys was apparent in all mice, indicating adequate
dye perfusion.
IN-infected mice have significantly higher
proinflammatory cytokine expression in the brain than
FP-inoculated mice
To gain a more detailed understanding of the inflammatory
response in the CNS, we evaluated inflammatory gene expression
in the brains of IN- and FP-inoculated mice. We found that both
groups demonstrated a mild increase in expression of CCL2, IL-6
and TNFa 6 dpi. However mice inoculated IN, but not FP,
displayed significant upregulation of several key inflammatory
cytokines 8 dpi, including CCL2, CCL5, IL-6 and TNFa,
(Figure 8 A-D) that coincided with the development of severe
clinical disease.
IN-infected mice had evidence of widespread viral
infection throughout the CNS at late time points
In order to determine the distribution of leukocytes infiltrating
the CNS, we evaluated the brains of moribund IN-inoculated mice
using histology and IHC. RVFV specific IHC suggested viral entry
most likely occurred through olfactory bulbs (Figures 9A and 9B),
and multifocal staining throughout the brain was consistent with
subsequent vascular and transneural spread of virus. Meningoen-
cephalitis was present and associated with the presence of viral
antigen (Figures 9C and 9D). Inflammatory foci were associated
with morphologic indications of apoptosis, viral antigen, a CD68+
microglial response and the presence of CD3+ cells (Figure 9 E-H)
Depletion of T cells has no effect on mortality following
IN infection
To explore the possibility that the onset of neurologic disease is
dependent on immune-mediated pathology, we depleted mice of
CD4+ and CD8+ T cells prior to DNSs IN infection. However, no
differences were observed in terms of clinical signs, mortality, or
time to death between CD4/CD8-depleted mice and mock-
depleted mice (Figure 10).
Discussion
Encephalitis is a serious and occasionally fatal complication
of human RVFV infection, however, little is known about the
factors contributing to this disease outcome. There are
currently no approved vaccines for human use and no
treatment exists beyond supportive care. Development of
efficacious preventative and therapeutic measures requires a
more detailed understanding of disease pathogenesis, including
the kinetics of virus replication and spread, the modes of
neuroinvasion, and the protective and potentially pathologic
roles of the host immune response. These studies are ideally
approached by comparing data from a fatal mouse model of
RVFV encephalitis with data from a nonfatal RVFV infection
in mice. Here, we demonstrate that DNSs virus intranasal
inoculation consistently caused fatal neurologic disease 7–
9 dpi, a finding that stands in stark contrast to the absence of
clinical disease following subcutaneous administration of the
Figure 6. T cells from FP-inoculated mice mount a robust
proinflammatory response in the spleen. Splenocytes were
prepared from IN- and FP-inoculated mice and used in ELISPOT assays
for proinflammatory cytokines including (A) IFNc, (B) TNFa, and (C) IL-2.
Means based on groups of 3 mice per time point.
doi:10.1371/journal.pntd.0002874.g006
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virus. Similarly, route-dependent clinical disease was recently
described in a mouse model of Hendra virus; mice inoculated
parenterally did not develop clinical signs but fatal encephalitis
developed following intranasal exposure [22]. Our results also
correlate well with those from recent studies that demonstrated
enhanced neurovirulence of wild-type RVFV when adminis-
tered as an aerosol in nonhuman primates [36] and rodents
[24,37].
Comparison of immunocompetent mice inoculated FP or IN
permitted characterization of the viral kinetics and immune
Figure 7. More activated CD69+ T cells infiltrated the brains of IN- than FP-inoculated mice. Leukocytes were isolated from the brains of
IN- and FP-inoculated mice. In an initial experiment, of the proportion of (A) CD45+ cells that were (B) CD3+ T cells were determined. In a follow-up
experiment, the proportion of (C) CD4+ and (D) CD8+ T cells in the brains of IN-inoculated mice and FP-inoculated mice were determined. The
proportion of T cells that stained positive for activation marker CD69 are shown in (E) CD3+/CD4+/CD69+ and (F) CD3+/CD8+/CD69+.Means based on
groups of 3 mice per time point.
doi:10.1371/journal.pntd.0002874.g007
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responses associated with nonfatal and fatal outcomes, respective-
ly. Interestingly, viral RNA loads were similar in peripheral tissues
by 2–3 dpi, presumably due to hematogenous spread from the
initial sites of virus replication. However, the route of inoculation
had a dramatic effect on the quality of the systemic host response;
FP-inoculated mice mounted a more rapid and effective immune
response than IN-inoculated mice. A robust humoral response, as
measured by significantly earlier and higher anti-RVFV IgG and
neutralizing antibodies, was associated temporally with early viral
clearance from peripheral tissues. Later in infection, FP-inoculated
mice initiated a strong T cell response, with significantly higher
production of IFNc, TNFa and IL-2 than IN-inoculated mice.
Studies of other encephalitis-associated viruses have shown that
IFNc and TNFa can play a critical role in controlling viral
replication in the CNS. For example, in a Japanese encephalitis
virus (JEV) model, IFNc knock-out mice had higher virus RNA
titers in brain than wild-type mice, but peripheral tissues have
similar viral RNA loads [38], a pattern similar to that seen in our
RVFV study, where production of IFNc was associated with better
control of virus. Similarly, following peripheral infection with
herpes simplex virus, production of TNF protected mice from
development of severe encephalitis [39]. These results suggested
that FP inoculation, but not lethal IN inoculation, stimulated a
highly effective adaptive immune response that supported viral
clearance and prevented progression to clinical disease.
Paradoxically in IN-infected mice, very early in infection there
was evidence of enhanced activation of T cells as compared with
FP-inoculated mice. These mice produced significant levels of IL-
2, a cytokine required for the proliferation and differentiation of T
cells (as reviewed in [40]) and enhanced natural killer cell activity
[41], that correlated temporally with a marked increase in the
proportion of T cells expressing the activation marker CD69.
However, in contrast to FP-inoculated mice, the T cells of IN-
inoculated mice did not produce IFNc or TNFa, cytokines
associated with the initiation of an appropriate adaptive response
and subsequent viral control. The presence of activated T cells
that lack effector function has been described previously in models
of other neurotropic viruses, including lymphocytic choriomenin-
gitis virus (LCMV) [42] and rabies virus [43]. CNS infection with
a highly neurotropic strain of rabies virus resulted in increased
expression of CD69 on T cells, but reduced production of
inflammatory cytokines IL-2, TNFa and IFNc. The authors
concluded that the apparent T cell ‘unresponsiveness’ resulted
from virally-induced immunosuppression specifically targeting the
CD4+ helper T cell response [43]. The effect of route of infection
on CD4+ helper T cell function during RVFV infection remains to
be evaluated in further detail.
The profound effect of the route of inoculation on host immune
response and clinical outcome may be explained, at least in part,
by differences in the nature of the immune cells encountered
following the initial inoculation. After FP infection, virus
immediately encounters resident dendritic (Langerhans) cells
and macrophages of the skin. These cells are professional
antigen-presenting cells (APCs), and upon recognition of viral
antigen, migrate to the draining lymph node to stimulate an early
immune response. In contrast, intranasal inoculation resulted in
rapid infection in the CNS. There are no detectable dendritic cells
in the CNS and microglia are considered poor APCs and limited
in the ability to initiate an adaptive response (reviewed in [44]).
The delay between initial IN inoculation and systemic infection,
Figure 8. IN-inoculated mice displayed a strong proinflammatory cytokine response in the brain 8 dpi. Gene expression of several
proinflammatory cytokines in the cerebrum of IN- and FP-inoculated mice was quantified by qRT-PCR, including (A) CCL2, (B) CCL5, (C) IL-6, and (D)
TNFa. A housekeeping gene (GAPDH) was used to normalize gene expression data between all samples. Relative fold change was calculated by
comparing expression in infected (IN or FP) tissues with mock-infected samples. Means based on groups of 5 mice per time point.
doi:10.1371/journal.pntd.0002874.g008
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coupled with the immunologically privileged nature of the CNS,
may help explain the lagging immune response and subsequently
enhanced viral replication in IN-inoculated mice.
Viral RNA loads were significantly higher in the brains of IN-
relative to FP-inoculated mice, despite similar virus RNA loads in
peripheral tissues, suggesting that the timing and mechanism of
neuroinvasion were route-dependent. When administered IN, the
virus rapidly infected the olfactory bulb and spread caudally to the
cerebrum and cerebellum. Multifocal distribution of viral antigen
was apparent, suggesting hematogenous and transneural spread
from the olfactory bulb. Indeed, active RVFV infection of
neuroepithelium and the olfactory bulb have been recently
reported [24], strongly supporting neuroinvasion through the
olfactory tract in intranasally exposed mice. On the other hand,
FP-inoculated mice had virus RNA-positive sciatic nerves 2 dpi,
with virus detected several days later in the CNS, and particularly
the brainstem, suggesting DNSs virus might utilize retrograde
transport to access the CNS. Infection of the peripheral nerves of
IN-inoculated mice coincided with increasing virus RNA loads in
the brainstem, suggesting that axonal virus transport might also
occur in the form of anterograde transport.
In light of the apparent hematogenous spread of virus and the
presence of cellular infiltrate in the CNS, we evaluated the
possibility that virally induced alterations in blood brain barrier
permeability led to the onset of clinical disease. In models of JEV
[45] and Venezuelan equine encephalitis virus (VEEV) [46]
development of viral encephalitis has been linked to inflammatory-
mediated alterations in BBB permeability either as a primary
mechanism of neuroinvasion or as a mediator of immunopathol-
ogy. Late stage RVFV has been associated with an increase in
proinflammatory cytokines and chemokines [47], Furthermore, in
this study, upregulation of IL-6, TNFa, CCL2 and CCL5 gene
expression in the brains of IN-inoculated mice was associated with
high virus RNA loads and infiltration of large numbers of
Figure 9. Infection of DNSs virus IN causes meningoencephalitis with inflammatory foci characterized by apoptosis and presence of
viral antigen, T cells and microglia. Tissues were processed, paraffin-embedded, and sectioned following routine methods, and stained with
hematoxylin and eosin (H&E) for histological examination. Immunohistochemistry (IHC) was performed using a monoclonal Rift Valley fever virus
antibody to visualize viral antigen and with anti-CD3, anti-CD8, anti-CD20 and anti-CD68 antibodies to identify inflammatory cells. Viral entry
appeared to be through the olfactory bulb: (A) H&E and (B) RVFV specific IHC. Meningoencephalitis with multifocal antigen staining is suggestive of
subsequent hematogenous spread: (C) subcortical area, H&E and (D) same area, RVFV specific IHC. Inflammatory foci were characterized by (E)
morphologic appearance of apoptosis and the presence of (F) RVFV antigen, (G) CD68+ microglia, and (H) CD3+ cells.
doi:10.1371/journal.pntd.0002874.g009
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aberrantly activated CD4+ and CD8+ T cells. However, to our
surprise we found no indication of increased BBB permeability in
the mice, even at the height of the CNS inflammatory response,
indicating that BBB disruption is not required for RVFV
pathogenesis.
Although there were no overt alterations in BBB perme-
ability, it was possible that T cell infiltration and associated
upregulation of inflammatory cytokines alone might have
enhanced neurovirulence, as seen in other models of viral
encephalitis [26,27,48]. Induction of these cytokines and
chemokines amplify the antiviral response and recruit leuko-
cytes, but if left unchecked, can have destructive effects. In the
brains of moribund IN-inoculated mice, a diffuse meningoen-
cephalitis was present and characterized by apoptosis in the
presence of viral antigen, T cells and CD68+ microglia. To
determine if the T cells played a pathologic role in the
development of neurologic disease, we depleted mice of both
CD4+ and CD8+ T cells prior to DNSs virus intranasal
infection. Strikingly, we observed no improvement in survival
of T cell-depleted mice relative to mock-depleted mice. These
results indicate that the development of RVFV encephalitic
disease is not T cell-mediated, and instead suggests that direct
viral damage is responsible for the onset of severe disease.
In summary, we developed a mouse model of fatal RVFV
encephalitic disease utilizing intranasal inoculation with an
attenuated RVFV. Fatal human cases of RVFV encephalitis are
relatively uncommon, and there are few descriptions of the CNS
pathology. However, the available case reports from South Africa
and Egypt describe focal areas of necrosis with perivascular cuffing
[49] and degeneration of the cerebral neurons with infiltration of
microglial cells [50]. Although these findings are fairly nonspecific,
they are similar to the lesions seen in the intranasally infected
mice, suggesting this is a reasonable model of RVFV encephalitis.
Comparison of the course of disease following IN or FP
inoculation of DNSs virus highlighted the potential roles of the
host immune response in determining clinical outcome. IN
inoculation resulted in rapid and fulminant virus replication in
the CNS via infection of the olfactory bulb, whereas FP-inoculated
mice had low virus RNA loads in the CNS and survived without
developing disease. Despite different outcomes, peripheral virus
kinetics were the same following both routes of inoculation, until
viral clearance, associated with a robust antibody response,
occurred exclusively in FP-inoculated mice. IN-inoculated mice
displayed an inappropriate T cell response; although apparently
activated, T cells failed to release critical cytokines for control of
virus replication. The ineffective adaptive immune responses of
IN-inoculated mice were associated with the development of peak
virus RNA loads, strong proinflammatory responses and infiltra-
tion of activated T cells into the CNS, followed by severe clinical
disease and death. Interestingly, in contrast to other encephalitic
viruses, T cells were not required for development of neurologic
disease, suggesting that RVFV encephalitis is not immune-
mediated. Although we cannot exclude a role for inflammatory
cytokines and other immune cells in the development of clinical
disease, our studies strongly point to direct viral destruction of the
brain as the major cause. These findings have implications for the
development of therapeutics targeting RVFV neurologic disease,
which may be particularly useful given the relatively delayed onset
of RVFV encephalitis in infected humans.
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